Pharmacotherapy for obese adolescents.

Donald E Greydanus, Lee A Bricker, Cynthia Feucht

Journal: Pediatric clinics of North America 2011;58(1):139-53, xi

PMID: 21281853

Full Text on Elsevier Science View on PubMed

Abstract

The pharmaceutical search to induce weight loss was precipitated by the United States Food and Drug Administration's (FDA) 1959 formal approval of phentermine for short-term weight loss despite limited research supporting its assertions of weight loss. In addition to sympathomimetic amine products like phentermine, other medications considered in this article include herbal products, sibutramine, orlistat, metformin, and rimonabant. The use of pharmacotherapy for morbidly obese adolescents should be part of a comprehensive weight-loss program that recommends diet, exercise, and behavioral modification. Side effects and the possibility of major adverse effects should be remembered when considering use of these products.

Address: Department of Pediatrics and Human Development, Michigan State University College of Human Medicine, Kalamazoo, MI 49009-1284, USA. [email protected]

DOI: 10.1016/j.pcl.2010.10.007

Link outs

Free resources

Medical:

https://medlineplus.gov/obesity.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Adolescent, Amphetamines, Anti-Obesity Agents, Anticonvulsants, Antidepressive Agents, Central Nervous System Stimulants, Ciliary Neurotrophic Factor, Herbal Medicine, Humans, Hypoglycemic Agents, Metformin, Obesity, Piperidines, Pyrazoles, Rimonabant